High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors

被引:14
|
作者
Ikezono, Yu [1 ,2 ]
Koga, Hironori [1 ,2 ]
Abe, Mitsuhiko [1 ,2 ]
Akiba, Jun [3 ]
Kawahara, Akihiko [2 ,4 ]
Yoshida, Takafumi [1 ,2 ]
Nakamura, Toru [1 ,2 ]
Iwamoto, Hideki [1 ,2 ]
Yano, Hirohisa [3 ]
Kage, Masayoshi [2 ,4 ]
Sata, Michio [1 ]
Tsuruta, Osamu [1 ]
Torimura, Takuji [1 ,2 ]
机构
[1] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka 8300011, Japan
[2] Kurume Univ, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 8300011, Japan
[3] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan
[4] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka, Japan
关键词
carcinoids; neuroendocrine tumor; cancer stem cell; NANOG; DOUBLECORTIN-LIKE; NEUROBLASTOMA-CELLS; PANCREATIC-CANCER; TUFT CELLS; MECHANISM; INTESTINE; MIGRATION; GROWTH;
D O I
10.3892/ol.2015.3513
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Doublecortin-like kinase 1 (DCLK1), a microtubule-associated protein, is known to regulate neuronal differentiation, migration and neurogenesis. Recent evidence suggests that the protein is a putative marker for intestinal and pancreatic stem cells, including their cancer stem cell counterparts. The present study conducted immunohistochemical analyses for DCLK1 and the sternness marker, NANOG, in human intestinal neuroendocrine tumors (NETs), as their expression had not been previously investigated in these tumors. Eighteen patients with endoscopically resected rectal NETs were enrolled in the study. The mean age of the patients was 51 years old. The mean diameter of the resected tumors was 5.2 mm, and a histological diagnosis of NET grade G1 was formed for all tumors. Immunohistochemical analysis was performed not only for DCLK1, but also for the known NET markers, synaptophysin, chromogranin A and cluster of differentiation (CD)56. The intensity and distribution of staining were scored on a scale of 0-3 and 0-2, respectively. The sum of the scores was calculated for each specimen. Co-expression of DCLK1 and NANOG was also examined. The mean scores for DCLK1 and synaptophysin were significantly higher than those for chromogranin A (P<0.0001) and CD56 (P<0.01). There were no significant differences in the scores between DCLK1 and synaptophysin or between chromogranin A and CD56. Notably, NANOG was expressed in high quantities in all the tumor tissues studied, showing clear co-expression with DCLK1. In conclusion, DCLK1 may be a novel marker for rectal NET, potentially indicating the presence of the sternness gene product, NANOG.
引用
收藏
页码:2015 / 2020
页数:6
相关论文
共 50 条
  • [21] DCLK1 Promotes Pancreatic Cancer Cell Clonogenicity and Invasiveness
    Qu, Dongfeng
    Weygant, Nathaniel
    Berry, William L.
    May, Randal
    Chandrakesan, Parthasarathy
    Sureban, Sripathi M.
    Houchen, Courtney W.
    GASTROENTEROLOGY, 2015, 148 (04) : S572 - S573
  • [22] Evaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methods
    Mirzaei, Alireza
    Madjd, Zahra
    Kadijani, Azade Amini
    Tavakoli-Yaraki, Masoumeh
    Modarresi, Mohammad Hossein
    Verdi, Javad
    Akbari, Abolfazl
    Tavoosidana, Gholamreza
    CANCER BIOMARKERS, 2016, 17 (03) : 301 - 311
  • [23] Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis
    Ito, Hiromitsu
    Tanaka, Shinji
    Akiyama, Yoshimitsu
    Shimada, Shu
    Adikrisna, Rama
    Matsumura, Satoshi
    Aihara, Arihiro
    Mitsunori, Yusuke
    Ban, Daisuke
    Ochiai, Takanori
    Kudo, Atsushi
    Arii, Shigeki
    Yamaoka, Shoji
    Tanabe, Minoru
    PLOS ONE, 2016, 11 (01):
  • [24] DCLK1 Marks a Morphologically Distinct Subpopulation of Cells With Stem Cell Properties in Preinvasive Pancreatic Cancer
    Bailey, Jennifer M.
    Alsina, Janivette
    Rasheed, Zeshaan A.
    McAllister, Florencia M.
    Fu, Ya-Yuan
    Plentz, Ruben
    Zhang, Hao
    Pasricha, Pankaj J.
    Bardeesy, Nabeel
    Matsui, William
    Maitra, Anirban
    Leach, Steven D.
    GASTROENTEROLOGY, 2014, 146 (01) : 245 - 256
  • [25] MicroRNA-137 Is Inversely Correlated with DCLK1, Which Is a Potential Distinct Marker for Colon Cancer Stem Cells
    Sakaguchi, Masazumi
    Hisamori, Shigeo
    Oshima, Nobu
    Sakai, Yoshiharu
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 221 (04) : S33 - S33
  • [26] Knocking down the expression of DCLK1 reduces mammary tumor formation, tumor cell self-renewal and metastasis: DCLK1 a novel therapeutic target in breast cancer
    Chandrakesan, Parthasarathy
    Weygant, Nathaniel
    Qu, Dongfeng
    Berry, William
    May, Randal
    Ali, Naushad
    Sureban, Sripathi
    Bannerman-Menson, Eddie
    Schlosser, Michael
    Houchen, Courtney
    CANCER RESEARCH, 2016, 76
  • [27] A tumor stem cell marker DCLK1 promotes hepatocellular carcinoma by regulating β-catenin, EMT and clonogenic properties of hepatocytes
    Ali, Naushad
    Nguyen, Charles B.
    Chandrakesan, Parthasarathy
    May, Randal
    Dhanasekaran, Danny
    Bronze, Michael S.
    Houchen, Courtney W.
    CANCER RESEARCH, 2017, 77
  • [28] Short (S) Isoform of Cancer-Stem-Cell Marker, DCLK1, Is Critically Required for Maintaining Proliferative/Tumorigenic Potential of Human Colon Cancer Cells (hCCCs) Independent of DCLK1-L Isoform
    O'Connell, Malaney R.
    Sarkar, Shubhashish
    Ward, Denise
    Singh, Pomila
    GASTROENTEROLOGY, 2016, 150 (04) : S605 - S605
  • [29] The tumor stem cell marker doublecortin-like kinase (DCLK1) activates inflammatory and carcinogenic signals in hepatocellular carcinoma
    Ali, Naushad
    Chandrakesan, Parthasarathy
    Nguyen, Charles B.
    Husain, Sanam
    Gillaspy, Allison F.
    Huycke, Mark
    Berry, William L.
    May, Randal
    Qu, Dongfeng
    Weygant, Nathaniel
    Sureban, Sripathi M.
    Dhanasekaran, Danny N.
    Houchen, Courtney W.
    CANCER RESEARCH, 2015, 75
  • [30] Synergistic effect of gemcitabine and a Dclk1 inhibitor on pancreatic cancer cell survival
    Kawamura, Daichi
    Takemoto, Yoshihiro
    Nishimoto, Arata
    Tanaka, Toshiki
    Hironaka, Yukari
    Yoshida, Kumiko
    Murakami, Junichi
    Kugimiya, Naruji
    Harada, Eijiro
    Ueno, Koji
    Hosoyama, Tohru
    Hamano, Kimikazu
    CANCER RESEARCH, 2017, 77